Roivant Sciences (ROIV) Gains from Sales and Divestitures (2022 - 2025)
Roivant Sciences (ROIV) reported Gains from Sales and Divestitures of $297795.0 for Q2 2025, down 86.62% on a YoY basis from $2.2 million in Q2 2024, and down 66.22% quarter-over-quarter from $881462.0 in Q4 2024.
Roivant Sciences (ROIV) Gains from Sales and Divestitures (2022 - 2025) Analysis & Trends
Roivant Sciences has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $297795.0 in Q2 2025.
- For the quarter ending Q2 2025, Gains from Sales and Divestitures fell 86.62% year-over-year to $297795.0; the trailing twelve-month figure through Jun 2025 stood at $297795.0 (down 86.62% YoY), and the FY2024 full-year result was $881462.0, down 7.78% from the prior year.
- Gains from Sales and Divestitures for Q2 2025 stood at $297795.0, down from $881462.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $3.9 million in Q3 2022, with the low at $297795.0 in Q2 2025.
- Historically, Gains from Sales and Divestitures has averaged $1.5 million across 4 years, with a median of $955782.0 in 2023.
- Annual changes were most pronounced in 2024 — Gains from Sales and Divestitures surged 583.37% — and 2025, when it plunged 86.62%.
- Roivant Sciences' Gains from Sales and Divestitures stood at $2.3 million in 2022, then tumbled by 58.37% to $955782.0 in 2023, then slipped by 7.78% to $881462.0 in 2024, then slumped by 66.22% to $297795.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $297795.0 (Q2 2025), $881462.0 (Q4 2024), and $585769.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 297,795.00 |
| Jun 30, 2025 | 297,795.00 |
| Dec 31, 2024 | 881,462.00 |
| Dec 31, 2024 | 881,462.00 |
| Sep 30, 2024 | 585,769.00 |
| Sep 30, 2024 | 585,769.00 |
| Jun 30, 2024 | 2.23 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 955,782.00 |
| Dec 31, 2023 | 955,782.00 |
| Sep 30, 2023 | 628,971.00 |
| Sep 30, 2023 | 628,971.00 |
| Jun 30, 2023 | 325,655.00 |
| Jun 30, 2023 | 325,655.00 |
| Mar 31, 2023 | 2.63 Mn |
| Mar 31, 2023 | 2.63 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Dec 31, 2022 | 2.30 Mn |